首页 / 院系成果 / 成果详情页

Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury  期刊论文  

  • 编号:
    ef0bdcad-0da6-4603-a810-eea8f79c0c8d
  • 作者:
    Zhang, Jing(张静)#[1]Guo, Ying[1];Jin, Qi[1];Bian, Li*[2]Lin, Ping*[3]
  • 语种:
    English
  • 期刊:
    DRUG DESIGN DEVELOPMENT AND THERAPY ISSN:1177-8881 2018 年 12 卷 (3685 - 3690)
  • 收录:
  • 关键词:
  • 摘要:

    Background: Contrast-induced nephropathy (CIN) is a complication after the intravascular administration of a contrast medium injection. Previous studies have investigated statins as therapy for CIN due to its positive results in the prevention of contrast-induced acute kidney injury (CI-AKI). Nevertheless, the beneficial effects of rosuvastatin pretreatment in preventing CIN in patients with acute coronary syndromes still remain controversial. In this study, we performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the beneficial impact of rosuvastatin in the prevention of CI-AKI in acute coronary syndrome patients. Methods: PubMed, Embase, and Cochrane library were searched, for RCTs, updated on January 2018. The method was to evaluate rosuvastatin prior to angiography for the prevention of CI-AKI in patients undergoing coronary angiography, of which the main outcome was the incidence of CIN. Results: A total of five RCTs were included in this analysis. Patients treated with rosuvastatin prior to invasive angiography had a significantly lower incidence of CI-AKI than controls (odds ratio [OR]: 0.53, 95% CI: 0.40-0.71, P<0.0001). Moreover, the subgroup analysis also showed that the benefit of rosuvastatin for patients with chronic kidney disease (OR: 0.49, 95% CI: 0.26-0.92, P=0.03) and diabetes mellitus (OR: 0.56, 95% CI: 0.38-0.83, P=0.004) which was consistent in compared with the respective control groups. Conclusion: The findings of this meta-analysis suggest that the preoperative rosuvastatin treatment significantly reduces the risk of renal insufficiency of CIN in at-risk patients with chronic kidney disease or diabetes mellitus. Additional studies are needed to identify at-risk patients, provide optimum dose peri-procedural treatment, and reduce the incidence of CIN.

  • 推荐引用方式
    GB/T 7714:
    Zhang Jing,Guo Ying,Jin Qi, et al. Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury [J].DRUG DESIGN DEVELOPMENT AND THERAPY,2018,12:3685-3690.
  • APA:
    Zhang Jing,Guo Ying,Jin Qi,Bian Li,&Lin Ping.(2018).Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury .DRUG DESIGN DEVELOPMENT AND THERAPY,12:3685-3690.
  • MLA:
    Zhang Jing, et al. "Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury" .DRUG DESIGN DEVELOPMENT AND THERAPY 12(2018):3685-3690.
  • 条目包含文件:
    文件类型:PDF,文件大小:
    正在加载全文
浏览次数:11 下载次数:0
浏览次数:11
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部